Industry Wants US Rebate Reform, But What Does That Mean?
Drug makers are bracing for a potential new policy change around rebating that could change the way they price drugs and negotiate market access. But some in the industry are advocating for a less disruptive new discounting system over the elimination of rebates all together.
You may also be interested in...
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.
After delaying the launch of the MS treatment due to the pandemic, Bristol now says the market is ready for a new launch. Immunology US business unit head Tina Deignan talked to Scrip about it.